Research prototype, not medical advice.

In a phase 1 trial (9 patients with diabetic kidney disease), 3 days of D+Q reduced senescent cells in fat and skin 11 days later: first direct proof in humans.

Confidence
Established
Level of evidence
Randomized clinical trial
Observed in
Human
Mission
Map of aging (12 hallmarks)
Concepts
Cellular senescenceDasatinib + quercetin (D+Q)Chronic kidney disease

What the sources say

Each row is an article. “Supports”: it backs the claim. “Contradicts”: it goes against it. “Qualifies”: it limits it (another species, a weaker effect…).

DirectionSourceWhere in the articleStatus
Supports Senolytics decrease senescent cells in humans: Preliminary report from a clinical trial of Dasatinib plus Quercetin in individuals with diabetic kidney disease
Hickson et al. · EBioMedicine 2019
— Verified

Related claims